Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Metagenomi, Inc. ( (MGX) ) has shared an announcement.
On May 14, 2025, Metagenomi, Inc. announced the presentation of three abstracts at the ASGCT 28th Annual Meeting, showcasing advancements in genome editing technologies. The data highlighted the potential of their compact nucleases for efficient gene editing and the CAST system for precise large gene integration, marking significant progress in developing in vivo precision medicines. These advancements could impact the treatment of neurological disorders and other diseases caused by loss-of-function mutations, enhancing Metagenomi’s position in the gene editing industry.
The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.
Spark’s Take on MGX Stock
According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.
Metagenomi, Inc. shows robust revenue growth, but significant challenges remain in profitability and cash flow management. The technical analysis indicates a bearish trend, while the valuation reflects potential financial distress due to negative earnings. Positive corporate developments provide some optimism, yet the overall financial and operational hurdles weigh heavily on the stock’s outlook.
To see Spark’s full report on MGX stock, click here.
More about Metagenomi, Inc.
Metagenomi, Inc. is a precision gene editing company that utilizes artificial intelligence and machine learning to develop next-generation genome editing therapeutics. The company focuses on creating potentially curative therapies for genetic mutations across the human genome, with a comprehensive platform that includes ultra-small nucleases, base editors, and CRISPR-associated transposase systems. Metagenomi’s pipeline includes a lead program for Hemophilia A and additional assets for secreted protein deficiencies and cardiometabolic diseases.
Average Trading Volume: 400,697
Technical Sentiment Signal: Sell
Current Market Cap: $57.94M
For detailed information about MGX stock, go to TipRanks’ Stock Analysis page.